Stifel raised the price target for the Genesis Healthcare Inc. (NYSE:GEN) stock from “a Hold” to “a Buy”. The rating was released on November 29, 2018. We previously noted in another research note published on November 21, 2016 by RBC Capital Mkts that downgraded the stock from an Outperform to a Sector perform with a price target of $3.50 for GEN stock. The research report from RBC Capital Mkts has reiterated the stock to Outperform, with a price target set at $3. The stock was downgraded by BofA/Merrill, who disclosed in a research note on May 16, 2016, from Neutral to Underperform. In their research brief published January 26, 2016, RBC Capital Mkts analysts reiterated the Genesis Healthcare Inc. stock to Outperform with a price target of $5.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.55 during the last quarter as opposed to a consensus estimate of -$0.36, which indicates the company missed its estimate by -$0.19, which implies that the company surprised the market by -52.80%. It appears that the average earnings per share estimate for the current quarter (ending in Dec 2020) is $0. This is an average of 0 analysts’ earnings, where the high earnings per share estimate is $0 and the low earnings per share estimate is $0. According to 2 analyst estimates, an average revenue estimate of $919.06M is projected for the current quarter with a high revenue estimate of $927.67M and a low estimate of $919.31M.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Genesis Healthcare Inc. (NYSE:GEN) dipped -12.71% to close Thursday’s market session at $0.42, lower as compared to yesterday’s close. The stock price fluctuated between $0.4204 and $0.4974 throughout the trading session with the volume trading being 15355989 shares, which represented a significant variation when compared to the three months average volume of 7.05 million shares. The firm’s stock price fluctuated -21.11% within the last five trades and -51.16% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -31.90% in the last 6 months and -21.48% was subtracted to its value over the previous 3 months. GEN stock is trading at a margin of -29.08%, -42.49% and -35.70% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, GEN deals in the Healthcare domain. The stock is trading -69.31 percent below its 52-week high and 4.84 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -44.62. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Genesis Healthcare Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 0.40 percent and the profit margin is -1.50 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $62.50 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The stock has achieved an effective Price-to-Sales Ratio of 0.02 that mirrors the cost to be found for sales by the market.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.30 percent of Genesis Healthcare Inc. shares are owned by insiders, and 16.90 percent are held by financial institutions. DiVittorio Thomas, the EVP and CFO at Genesis Healthcare Inc. (GEN) has sold 6,671 shares of firm on Jun 03 at a price of $0.95 against the total amount of $6371.0. In another inside trade, Reifsnyder JoAnne Susan, EVP and Chief Nursing Officer of Genesis Healthcare Inc. (NYSE:GEN) sold 5,313 shares of the firm on Jun 03 for a total worth of $5074.0 at a price of $0.95. An inside trade which took place on Jun 03, SVP and Treasurer of Genesis Healthcare Inc. Young Stephen Scott sold 3,315 shares of firm against total price of $3166.0 at the cost of $0.95 per share.